Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005778 · ClinicalTrials.gov registry record · Phase 3
High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide
A Phase 3 study, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00005778 is a Phase 3 study that has completed, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The registered enrollment target is 100 participants.
The verdict
NCT00005778, a Phase 3 study, has completed, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study compares the effectiveness of high-dose cyclophosphamide treatment with the "gold standard" treatment, monthly intravenous (IV) cyclophosphamide, in people with moderate to severe lupus that does not respond to high-dose corticosteroid therapy. We will give patients either IV cyclophosphamide (750 milligrams per square meter of body surface area) monthly for 6 months, followed by quarterly maintenance therapy, or high-dose IV cyclophosphamide (50 milligrams per kilogram body weight per day) for the first four days of the study. Patients will be followed for 24 months after therapy.
Interventions
- DRUG High-dose immunoablative therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2000-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)93 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005778
The ClinicalTrials.gov registry entry for NCT00005778 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which High-dose immunoablative therapy is the first listed.
NCT00005778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005778 about?
NCT00005778 is a clinical study titled "High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide". This study compares the effectiveness of high-dose cyclophosphamide treatment with the "gold standard" treatment, monthly intravenous (IV) cyclophosphamide, in people with moderate to severe lupus that does not respond to high-dose corticosteroid therapy. We will give patients either IV cyclophospha...
What is the current status of trial NCT00005778?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2000-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00005778?
The interventions under investigation include: High-dose immunoablative therapy (DRUG).
Who is sponsoring clinical trial NCT00005778?
This trial is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.